Inflammatory bowel disease

Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...

Many people with IBD still experience active disease, poor quality of life, work impairment, and depression even while on advanced therapies — highlighting gaps in how we measure and manage treatment success. Who this...

The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.

People with IBD often take biologics and may need or want implant-based breast surgery.

This mouse study identifies a novel peptide that reduced DSS-induced colitis and points to mast cells and fibroblast–mast cell interactions as potential therapeutic targets. It also showed additive benefit when combined...

This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from...

The analysis suggests genetic liability to IBD, particularly Crohn’s disease, may raise the risk of IgA vasculitis. This is relevant for understanding overlapping immune mechanisms and possible shared pathways between...

Nanotechnology is being heavily explored as a way to improve drug targeting, control release, and reduce systemic toxicity in IBD — topics that could shape future treatment options and research priorities.

Mood disorders commonly co-occur with chronic somatic diseases, including IBD; understanding shared mechanisms may explain worse outcomes and suggest multidisciplinary care needs.

Understanding which patients are at higher risk for serious complications after IBD surgery can help patients and clinicians weigh risks, plan preoperative optimization, and guide research into preventive strategies.

This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...

Lung inflammation can occur in children with IBD but is uncommon and may be hard to spot because symptoms can be vague or absent. Early recognition matters because imaging, bronchoscopy, and sometimes biopsy help...

The study explores a novel method to reduce gut oxidative stress — a contributor to IBD inflammation — by using an engineered probiotic to edit NOX2, which could point toward new therapeutic strategies if translated to...

Kidney dysfunction can occur in people with IBD and may be under-recognized. A validated prediction model could help clinicians identify IBD patients at higher risk and prompt earlier monitoring or interventions.

VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...

Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...

This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued...

Fecal incontinence is a distressing symptom that lowers quality of life and appears linked to active disease in UC. Knowing which patients are at higher risk can help clinicians focus assessment and symptom support.

If reliable, an earlier day‑3 PUCAI cutoff could help identify children with flare‑related ASUC who are unlikely to respond to IV steroids and who may benefit from earlier planning for second‑line therapy rather than...

Identifies a new molecular checkpoint (RADX versus IFI16) linking replication stress/genome instability to innate immune activation and intestinal inflammation, suggesting potential targets for future IBD treatments or...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery. The original article is from ANZ Journal of Surgery.

This article suggests a naturally derived compound (isorhamnetin) identified from TCM may reduce inflammation in experimental ulcerative colitis and points to the Nrf2–PTGS2 pathway as a possible mechanism. That could...

An infectious cause (amebic colitis) can mimic IBD on colonoscopy and imaging, even without symptoms; misdiagnosis could delay correct treatment.

Stoma creation and whether it can later be closed greatly affects daily life and planning for people with Crohn's disease.

The paper identifies microbiome-derived peptides that can directly block TLR4 signaling and reduce intestinal inflammation in mice; this reveals a new microbiome–immune mechanism that could inform future IBD treatments.

Metabolic syndrome appears common in this Tunisian IBD cohort (about one-third). MetS can affect overall health and may influence long-term outcomes for people with IBD, so awareness and cardiometabolic screening may be...

The study suggests a cellular redox pathway (selenium vs thiol axis) that is altered differently in Crohn's disease versus colorectal cancer, which could point to disease vulnerabilities and possible links to treatment...

The study suggests that in IBD the gut microbiome’s functional impact on immune signalling is shifted toward inflammation even when composition appears similar to controls.

A simple blood ratio measured before surgery (LCR) may help predict which children with UC are at higher risk of surgical site infection after IPAA, potentially guiding preoperative care.

Findings are relevant because they describe outcomes and predictors of conversion for a minimally invasive surgery option (SILS) that some patients with Crohn's disease may be offered. Understanding risk factors can help...

For patients hospitalized with steroid-refractory ASUC, an effective oral rescue option could be useful when standard biologics are unavailable or contraindicated. The study also highlights that high colonic CMV DNA may...

Elevated pancreatic enzymes are relatively common in IBD and can reflect very different conditions (benign asymptomatic elevations, pancreatitis variants, or autoimmune pancreatitis). Recognizing phenotype-specific...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from Journal of Crohn's & colitis.

The study links a traditional herbal formula to improved colitis in mice and to changes in bile-acid metabolism through the FXR–FGF15 pathway, suggesting a mechanistic route that could inform future preclinical or...

Researchers are investigating RBM47 because it influences RNA processing and immune pathways that could modify inflammation and disease processes relevant to IBD. If borne out, RBM47 could become a biomarker or...

B cells and antibodies appear to play active, regulatory roles in gut inflammation and tissue organization in IBD. Understanding this axis could inform new therapies or biomarkers that change how inflammation is detected...

If you have IBD and joint symptoms, this study suggests your joint complaints may reflect measurable immune changes that partly overlap with spondyloarthritis, not just non-specific pain. That could mean joint symptoms...

This paper describes a new engineered, off-the-shelf regulatory T cell therapy (TRX103) designed to restore immune tolerance and that is already entering early clinical trials for treatment-refractory Crohn’s disease.

Fatigue is a common, disabling symptom in people with IBD with unclear causes. Finding reproducible immune or infectious signatures related to fatigue could point toward new research directions and, eventually, markers...

Researchers identified a defined pectin from Sanguisorba officinalis that reduced inflammatory cytokine release in cells and improved outcomes in a mouse colitis model, suggesting a new lead for IBD drug discovery.

Mitochondrial dysfunction may contribute to IBD symptoms and disease progression; therapies that protect or restore mitochondrial function could become future treatment strategies. People interested in complementary or...

Sarcopenia is common in Crohn's disease and is linked to worse outcomes; a simple GNRI-based prediction tool could help identify at-risk patients without routine CT scanning.

Finding monogenic causes in infants with congenital diarrheas or VEOIBD can directly affect diagnosis, genetic counseling, and management. Populations with higher consanguinity may have higher diagnostic yields for...

Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...

Identifying genetic predictors of thiopurine-induced leukopenia could help prevent a serious drug side effect by improving pre-treatment genetic screening and dose decisions for people with IBD.

Blood-based inflammatory ratios like CRP/albumin were associated with higher odds of needing anti‑TNF therapy, colectomy, and longer hospital stays in moderate–severe UC, suggesting potential utility as complementary...

Perianal fistulas are a serious complication of Crohn’s disease with limited high-quality trial evidence. This randomized trial suggests ustekinumab may increase the chance of combined clinical and MRI remission at 12...